AstraZeneca’s Tagrisso Receives the US FDA’s Approval for Treating Unresectable, Stage III EGFR-Mutated Lung Cancer
Shots:
- The US FDA has approved Tagrisso to treat unresectable, EGFRm NSCLC (stage III) whose disease did not progress after Pt-based CRT, based on the P-III (LAURA) study. Data was highlighted at ASCO 2024 & published in the NEJM
- The P-III (LAURA) study assessed Tagrisso (80mg, QD, oral) vs PBO to treat patients (n=216) with unresectable, EGFRm NSCLC (stage III) not progressed after Pt-based CRT across various regions
- Study showed reduced risk of disease progression or death by 84% with an mPFS of 39.1mos. vs 5.6mos., OS data was not mature and is under evaluation. Safety & tolerability aligned with the previous profiles and did not show any new signals
Ref: Astrazeneca | Image: Astrazeneca
Related News:- AstraZeneca’s Tagrisso Plus Chemotherapy Receives Health Canada’s Approval to Treat Advanced Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
